Brooks Laboratories Limited (NSE:BROOKS)
India · Delayed Price · Currency is INR 61.00
+1.39 (2.33%)
Jul 31, 2026, 3:26 PM IST
Brooks Laboratories Financials Overview
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
| Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Revenue Revenue Growth | 857.38 | 857.38 | 825.57 | 794.86 | 632.05 | 911.85 |
Revenue Growth | 3.85% | 3.85% | 3.86% | 25.76% | -30.69% | 18.04% |
Gross Profit Gross Profit Growth | 347.17 | 347.17 | 279.36 | 225.13 | 107.95 | 272.06 |
Operating Income Operating Income Growth | 54.7 | 54.7 | 36.81 | 21.32 | -334.02 | -213.8 |
Net Income Net Income Growth | 245.84 | 245.84 | -99.67 | -195.92 | -208.92 | -112.9 |
Earnings Per Share EPS Growth | 8.35 | 8.35 | -3.72 | -7.65 | -8.46 | -4.57 |
EPS Growth | - | - | - | - | - | - |
| Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Trading Trading Growth | 28.66 | 28.66 | - | - | - | - |
Manufacturing Manufacturing Growth | 828.73 | 828.73 | - | - | - | - |
Pharmaceuticals Pharmaceuticals Growth | - | - | 825.57 | 794.86 | 632.05 | 911.85 |
Total Total Growth | 857.38 | 857.38 | 825.57 | 794.86 | 632.05 | 911.85 |
| Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Cash & Investments Cash & Investments Growth | 75.49 | 75.49 | 0.43 | 1.26 | 0.23 | 26.05 |
Total Debt Total Debt Growth | 85.17 | 85.17 | 75.83 | 56.42 | 65.12 | 252.59 |
Net Cash (Debt) Net Cash Growth | -9.68 | -9.68 | -75.39 | -55.16 | -64.89 | -226.54 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share Net Cash Per Share Growth | -0.33 | -0.33 | -2.81 | -2.15 | -2.63 | -9.17 |
| Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Operating Cash Flow Operating Cash Flow Growth | 92.93 | 92.93 | 26.26 | -98.01 | -144.9 | -374.41 |
Capital Expenditures CapEx Growth | -35.06 | -35.06 | -9.23 | -4.39 | -4.68 | -276.12 |
Free Cash Flow Free Cash Flow Growth | 57.88 | 57.88 | 17.04 | -102.4 | -149.58 | -650.53 |
Free Cash Flow Growth | 239.75% | 239.75% | - | - | - | - |
| Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Gross Margin | 40.49% | 40.49% | 33.84% | 28.32% | 17.08% | 29.84% |
Operating Margin | 6.38% | 6.38% | 4.46% | 2.68% | -52.85% | -23.45% |
Pretax Margin | 28.67% | 28.67% | -11.86% | -24.62% | -60.71% | -26.21% |
Profit Margin | 28.67% | 28.67% | -12.07% | -24.65% | -33.05% | -12.38% |
FCF Margin | 6.75% | 6.75% | 2.06% | -12.88% | -23.67% | -71.34% |
| Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 2, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
PE Ratio | 7.30 | 4.45 | - | - | - | - |
P/FCF Ratio | 31.04 | 18.89 | 185.94 | - | - | - |
PS Ratio | 2.10 | 1.27 | 3.84 | 3.09 | 2.44 | 1.98 |